Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
1633results about "Glycosyltransferases" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cells of which genome is modified
InactiveUS20040110704A1Raise the ratioDecreased and deleted activityAntibacterial agentsAntipyreticGlycosideN-Acetylglucosamine
A cell in which genome is modified so as to have a more decreased or deleted activity of an enzyme relating to modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through alpha-bond in a complex N-glycoside-linked sugar chain than its parent cell, and a process for producing an antibody composition using the cell.
Owner:KYOWA HAKKO KOGYO CO LTD
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.
Owner:KYOWA HAKKO KIRIN CO LTD
Polysaccharide fibers
This invention pertains to novel fibers made of α(1→;3) polysaccharides, and a process for their production. The fibers of the invention have “cotton-like” properties but can be produced as continuous filaments on a year-round basis. The fibers are useful in textile applications.
Owner:DUPONT IND BIOSCIENCES USA LLC
Methods for modifying human antibodies by glycan engineering
ActiveUS20110263828A1Improve efficacyImprove stabilityImmunoglobulinsFermentationGlycanAntibody fragments
Modified Fc regions of antibodies and antibody fragments, both human and humanized, and having enhanced stability and efficacy, are provided. Fc regions with core fucose residues removed, and attached to oligosaccharides comprising terminal sialyl residues, are provided. Antibodies comprising homogeneous glycosylation of Fc regions with specific oligosaccharides are provided. Fc regions conjugated with homogeneous glycoforms of monosaccharides and trisaccharides, are provided. Methods of preparing human antibodies with modified Fc using glycan engineering, are provided.
Owner:ACAD SINIC
Nucleic acids of aspergillus fumigatus encoding industrial enzymes and methods of use
The present invention provides nucleotide sequences of Aspegillus fumigatus that encode proteins which exhibit enzyme activities. Vectors, expression constructs, and host cells comprising the nucleotide sequences of the enzyme genes are also provided. The invention further provides methods for producing the enzymes, and methods for modifying the enzymes in order to improve their desirable characteristics. The activities displayed by the enzymes of the invention include those of a tannase, cellulase, glucose oxidase, glucoamylase, phytase, beta-galactosidases, invertase, lipase, alpha-amylase, laccase, polygalacturonase or xylanase. The enzymes of the invention can be used in a variety of industrial processes. Enzymatically active compositions in various forms as well as antibodies to the enzymes and fragments thereof, are also provided.
Owner:MERCK & CO INC
Fully active alternansucrases partially deleted in its carboxy-terminal and amino-terminal domains and mutants thereof
Nucleic acid sequences of truncated or mutated alternansucrases, vectors containing these nucleic acids sequences, host cells transformed with the nucleic acid sequences encoding truncated or mutated alternansucrases are provided. Furthermore, a process to recombinantly alternansucrase with a high level of expression, while retaining the enzymatic activity is described.
Owner:CENT NAT DE LA RECHERCHE SCI
High titer production of poly (α 1,3 glucan)
A process for enzymatic preparation of poly (α1, 3 glucan) from sucrose is disclosed. The glucosyltransferase enzyme (gtfJ) from Streptococcus salivarius is used to convert sucrose to fructose and poly (α1, 3 glucan). Application of semi-permeable membranes to continuously remove fructose, a by-product of the gtf enzyme, thus increasing the poly (α1, 3 glucan) liter, is disclosed.
Owner:NUTRITION & BIOSCIENCES USA 4 INC
Methods and compositions for producing double allele knock outs
The present invention provides a method and compositions utilizing the CRISPR system to disrupt a target gene in eukaryotic cells to produce double allele knock outs. The method finds use in producing afucosylated antibodies with enhanced ADCC activity.
Owner:LARIX BIOSCI
Antibody composition-producing cell
InactiveUS20060063254A1High activityReduced activityAntibacterial agentsAntipyreticDisease causeDisease injury
The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.
Owner:KYOWA HAKKO KIRIN CO LTD
IL3Ralpha antibody conjugates and uses thereof
ActiveUS20090252742A1Shorten the durationReduce severitySugar derivativesMicrobiological testing/measurementCancer cellAntibody conjugate
The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3Rα) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3Rα-expressing cell population, the methods comprising contacting a population of IL3Rα-expressing cells (e.g., cancer cells and / or cancer stem cells) with an antibody that binds to IL3Rα. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3Rα chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and / or managing a disorder associated with IL3Rα-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3Rα.
Owner:STEMLINE THERAPEUTICS
Bacteria-Mediated Therapy for Cancer
Methods for treating tumors and malignant tumors in regions that are adjacent to the gastrointestinal tract are provided. Therapeutically effective amounts of transformed bacteria are administered to subjects in need of treatment. Bacteria are transformed to produce proteins exhibiting therapeutic effects. These therapeutic effects can be the production of an enzyme that catalyzes the conversion of a prodrug into a drug and / or a protein that has therapeutic activity on its own. Bacteria may be provided to the gastrointestinal tract of the subject in need of treatment or preventative measures. In some cases, a prodrug is additionally administered.
Owner:HOVANKY VANNA
Compositions and methods for the treatment of autism
Compositions that may be usefully employed to alleviate symptoms resulting from deficiencies in carbohydrate enzymes, together with methods for the treatment of disorders that are characterized by such deficiencies, such as autism, are provided. The compositions preferably comprise transglucosidase isolated from A. niger.
Owner:KIRKMAN GROUP +1
Cells of which genome is modified
A cell in which genome is modified so as to have a more decreased or deleted activity of an enzyme relating to modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex N-glycoside-linked sugar chain than its parent cell, and a process for producing an antibody composition using the cell.
Owner:KYOWA HAKKO KIRIN CO LTD
Compositions and methods for the treatment of autism
Compositions that may be usefully employed to alleviate symptoms resulting from deficiencies in carbohydrate enzymes, together with methods for the treatment of disorders that are characterized by such deficiencies, such as autism, are provided. The compositions preferably comprise transglucosidase isolated from A. niger.
Owner:KIRKMAN GROUP +1
Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
InactiveUS20070134759A1High effector functionHighly functionalFungiSugar derivativesGlycosideAntiendomysial antibodies
The present invention provides a process for producing an antibody composition using a cell, which comprises using a cell into which an RNA having activity of suppressing the function of an enzyme relating to the modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex type N-glycoside-linked sugar chain is introduced; the RNA used in the production process; a DNA corresponding to the RNA; a cell in which the RNA or DNA is introduced or expressed; a process for producing the cell; and a method for suppressing the enzyme.
Owner:KYOWA HAKKO KIRIN CO LTD
Non-caloric sweetener
ActiveUS20150315623A1High sweetnessSugar derivativesAntibody mimetics/scaffoldsUdp glycosyltransferaseRebaudioside D
Disclosed is a steviol glycoside referred to as rebaudioside D2. Rebaudioside D2 has five β-D-glucosyl units connected to the aglycone steviol. Also disclosed are methods for producing rebaudioside D2, a UDP-glycosyltransferase fusion enzyme, and methods for producing rebaudioside D and rebaudioside E.
Owner:CONAGEN INC
Polypeptides having glucanotransferase activity and nucleic acids encoding same
InactiveUS6617143B1Organic detergent compounding agentsBacteriaNucleic acid sequencingNucleic acid sequence
The present invention relates to isolated polypeptides having glucanotransferase activity and isolated nucleic acid sequences encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing and using the polypeptides.
Owner:NOVOZYMES AS
Large scale enzymatic synthesis of oligosaccharides
ActiveUS20140051127A1Bioreactor/fermenter combinationsBiological substance pretreatmentsEnzymatic synthesisNucleotide
A novel UDP-Gal regeneration process and its combined use with a galactosyltransferase to add galactose to a suitable acceptor substrate. Also described herein are synthetic methods for generating Globo-series oligosaccharides in large scale, wherein the methods may involve the combination of a glycosyltransferase reaction and a nucleotide sugar regeneration process.
Owner:ACAD SINIC
Method and application for screening ultralow fucose cell line
The invention discloses a method and application for screening an ultralow fucose cell line. The invention provides a method for constructing fucose deficit type host cells capable of expressing an antibody and an IgG-FC fusion protein, a detection method for the fucose activity of the antibody and the IgG-Fc fusion protein, and concrete application of the cell lines. The method provided by the invention is realized by highly-efficient knockout of fucose-based transferase (FUT8) gene in an engineering cell producing the antibodies and the IgG-Fc fusion protein through a TALEN (and / or CRISPR) technology; and through lens culinaris lectin (LCA) pressurizing, gene sequencing and a flow cytometry screening process, the host cells with highly-efficiently knocked-out fucose is obtained. Meanwhile, fucose deficit CHOK1 host cell lines are constructed into stable engineering cell lines capable of expressing antibody proteins; and after the antibody proteins are obtained, glycoform analysis is performed; and results show that fucose knockout efficiency reaches to 99% or above.
Owner:XUANZHU BIOPHARMACEUTICAL CO LTD +1
Bacillus subtilis for efficient exogenous protein expression and high density culture
Belonging to the technical field of bioengineering, the invention discloses a bacillus subtilis for efficient exogenous protein expression and high density culture. According to the invention, a screening and separation method is employed to acquire a bacillus subtilis with high protein expression quantity, and the six genes srfC, spoIIAC, amyE, nprE, aprE and bamA are knocked out to obtain B. subtilis WS5 with a preservation number of CCTCC M 2016536. The bacillus subtilis WS5 is adopted as the expression host for construction of a beta-CGTase genetically engineered bacterium. The beta-CGTase genetically engineered bacterium is subjected to 3L fermentor culture, foams produced in the fermentation process are obviously decreased, a mirror does not detect spore production, almost no extracellular amylase and protease exist in the culture process, after 70h of fermentation culture, the beta-CGTase enzyme activity reaches 270U / ml, and DCW reaches 70g / L.
Owner:JIANGNAN UNIV
Alpha (1,2) Fucosyltransferases Suitable for Use in the Production of Fucosylated Oligosaccharides
ActiveUS20140031541A1Reduce severityReduce frequencyBacteriaLibrary screeningEscherichia coliFucosylation
The invention provides compositions and methods for engineering E. coli or other host production bacterial strains to produce fucosylated oligosaccharides, and the use thereof in the prevention or treatment of infection.
Owner:GLYCOSYN
Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof
InactiveUS20120328526A1Symptoms improvedBiocideNervous disorderNicotinamide ribosideNicotinamide mononucleotide
The present invention provides a method of treating a mammal having a neuropathophysiological condition, comprising the step of administering to the mammal in need of such treatment a compound selected from nicotinamide or salts or prodrugs thereof, nicotinamide mononucleotide or salts or prodrugs thereof, nicotinamide adenine dinucleotide or salts or prodrugs thereof, nicotinamide riboside nicotinamide or salts or prodrugs thereof, phosphoribosyltransferase, or combinations thereof. Further provided is a method for treating a mammal having a neuropathophysiological condition or suspected to develop said neuropathophysiological condition, comprising the step of administering to said mammal an inhibitor of CD38 NAD+ glycohydrolase activity.
Owner:BALITMORE UNIV OF MARYLAND
Composition and methods related to modification of 5-hydroxymethylcytosine (5-hmC)
Owner:UNIVERSITY OF CHICAGO
Methods of reversing drug resistance in cancer cells
This invention relates in general to methods and compositions for reversing the drug resistance of cancer cells. In particular this invention is directed to inhibition of drug resistance in cancer cells or to the induction of apoptosis in cancer cells by the use of glucosylceramide synthase antisense compounds. This invention is further directed to compositions comprising glucosylceramide synthase antisense compounds and a kit or drug delivery system comprising the compositions.
Owner:JOHN WAYNE CANCER INST
Recombinant production of steviol glycosides
Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to express novel recombinant genes encoding steviol biosynthetic enzymes and UDP-glycosyltransferases (UGTs). Such microorganisms, plants, or plant cells can produce steviol or steviol glycosides, e.g., rubusoside or Rebaudioside A, which can be used as natural sweeteners in food products and dietary supplements.
Owner:沃维公司
Genetic engineering cell line for producing unfucosylated protein and establishment method thereof
ActiveCN107217042AGenetic stabilityMicroorganism based processesFermentationFucosylationTherapeutic effect
The invention discloses a genetic engineering cell line for producing an unfucosylated protein and an establishment method thereof. The invention utilizes the CRISPR / Cas9 technique to knock out the Slc35cl gene and / or the Fut8 gene in host cells, and thereby the Slc35cl gene-silencing and / or Fut8 gene-silencing stable genetic engineering cell line is obtained. By utilizing the genetic engineering cell line disclosed by the invention, the protein from which fucosylation is completely removed can be produced, moreover, the protein is still stable after 30 generations of passage, and thereby the two major problems of incomplete fucosylation removal and unstable passage in the prior art are solved. An unfucosylated antibody produced by the method disclosed by the invention shows enhanced ADCC (antibody dependent cell-mediated cytotoxicity) activity, and thereby the clinical therapeutic effect of the antibody is enhanced.
Owner:江苏东抗生物医药科技有限公司
Sugar reduction of food products
ActiveUS20180146699A1Hydrolytic activity was lowHigh activityConfectionerySweetmeatsFood materialSugar
A process for reducing the monosaccharide and / or disaccharide content in a food material, the process comprising contacting the food material with a glucosyltransferase that comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 1.
Owner:SOC DES PROD NESTLE SA
Application of CRISPR/Cas9 carrier combination in preparation of blood product of gene knockout pig
PendingCN108588123AReduce the binding forceSolve the problem of ischemiaHydrolasesStable introduction of DNAWhole blood productRed Cell
The invention discloses the application of a CRISPR / Cas9 carrier combination in preparation of a blood product of a gene knockout pig. The gene knockout pig is a pig without GGTA1 genes, CMAH genes and beta4Ga1NT2 genes. The CRISPR / Cas9 carrier combination comprises a GGTA1-CRISPR / Cas9 carrier, a CMAH-CRISPR / Cas9 carrier and a beta4Ga1NT2-CRISPR / Cas9. By designing a specifically targeted SgRNA sequence, the knockout efficiency of the three genes is respectively 56 percent, 63 percent and 41 percent; after the three genes relating to immunological rejection are knocked out, the gene knockout pig is obtained; the combination between erythrocytes and immune globulin in human serum is obviously reduced; an outstanding effect is achieved to overcome hyperacute immunological rejection; the problem of clinical ischemia is effectively solved; a precious material source is provided for clinical blood transfusion.
Owner:GCREATENE SUZHOU BIOTECH CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com